Kodiak Sciences, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Patrick Dolezal from LifeSci Capital maintained a Buy rating on the stock and has a $40.00 price target.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Patrick Dolezal has given his Buy rating due to a combination of factors including Kodiak Sciences’ promising pipeline and recent data releases. The company has maintained its guidance for upcoming readouts, particularly with its KSI-101 asset, which has shown incremental improvements in visual acuity and central subfield thickness in patients with macular edema. This asset is pivotal to Kodiak’s strategy, especially given its competitive differentiation against Roche’s similar IL-6 asset, vamikibart, with KSI-101 demonstrating superior efficacy.
Additionally, Kodiak has completed enrollment for its Phase III DAYBREAK study with KSI-501 and tarcocimab, with top-line data expected in August 2026. The revised formulation used in these studies could enhance efficacy and address previous safety concerns. Although the analyst does not currently assign value to tarcocimab in their model, the potential improvements in product profile from these studies could significantly impact Kodiak’s valuation, providing a compelling investment opportunity.
In another report released on November 11, H.C. Wainwright also upgraded the stock to a Buy with a $24.00 price target.